Antiandrogens in Prostate Cancer A Key to Tailored Endocrine Treatment
The introduction of maximal androgen blockade as a clinical therapy by Brachi and Labrie more than a decade ago led to a huge controversy on the clinical use of antiandrogens in the treatment of prostate cancer. Three consensus meetings were subsequently organized with the support of the American Ca...
| Other Authors: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Berlin, Heidelberg
Springer Berlin Heidelberg
1996, 1996
|
| Edition: | 1st ed. 1996 |
| Series: | ESO Monographs, European School of Oncology
|
| Subjects: | |
| Online Access: | |
| Collection: | Springer Book Archives -2004 - Collection details see MPG.ReNa |
Table of Contents:
- Some Aspects of the Molecular Endocrinology of Prostatic Cancer
- Pharmacology of Cyproterone Acetate — A Short Review
- Cyproterone Acetate — Results of Clinical Trials and Indications for Use in Human Prostate Cancer
- Biological Properties of Flutamide
- Combination Therapy with Flutamide: The Therapy of Choice from Early to Advanced Stages of Prostate Cancer
- Casodex: Preclinical Studies
- Clinical Aspects of Casodex
- Pharmacodynamics and Pharmacokinetics of Nilutamide in Animal and Man
- A Review of the Clinical Studies with Nilutamide
- Indications for Antiandrogen Treatment in Prostate Cancer